Concentration of patient care among buprenorphine-prescribing clinicians in the us

Bradley D. Stein; Brendan Saloner; Megan S. Schuler; Jill Gurvey; Mark Sorbero; Adam J. Gordon

doi:10.1001/jama.2021.4469

Concentration of patient care among buprenorphine-prescribing clinicians in the us

Bradley D. Stein, Brendan Saloner, Megan S. Schuler, Jill Gurvey, Mark Sorbero, Adam J. Gordon

Bloomberg School of Public Health

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	2206-2208
Number of pages	3
Journal	JAMA - Journal of the American Medical Association
Volume	325
Issue number	21
DOIs	https://doi.org/10.1001/jama.2021.4469
State	Published - Jun 1 2021

ASJC Scopus subject areas

General Medicine

Access to Document

10.1001/jama.2021.4469

Cite this

@article{0edcfcf12b404528927b57be54454885,

title = "Concentration of patient care among buprenorphine-prescribing clinicians in the us",

author = "Stein, {Bradley D.} and Brendan Saloner and Schuler, {Megan S.} and Jill Gurvey and Mark Sorbero and Gordon, {Adam J.}",

note = "Funding Information: Funding/Support: This research was supported by grants R01DA045800, K01DA042139, 1UG1DA049444, and P50DA046351 from the National Institutes of Health. Role of the Funder/Sponsor: The National Institutes of Health had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Additional Contributions: We thank Mary Vaiana, PhD, and Hilary Peterson, BA (both with the RAND Corporation), for their feedback and editorial assistance on earlier versions of the manuscript; Rose Kerber, MPP (RAND Corporation), for assistance with the data; and Mark Totten, MS (RAND Corporation), for input regarding the analysis. None received additional compensation beyond their RAND salaries. 1. Frank JW, Wakeman SE, Gordon AJ. No end to the crisis without an end to the waiver. Subst Abus. 2018;39(3):263-265. doi:10.1080/08897077.2018.1543382 2. Olsen Y, Fitzgerald RM, Wakeman SE. Overcoming barriers to treatment of opioid use disorder. JAMA. 2021;325(12):1149-1150. doi:10.1001/jama.2021.1741 3. Thomas CP, Doyle E, Kreiner PW, et al. Prescribing patterns of buprenorphine waivered physicians. Drug Alcohol Depend. 2017;181:213-218. doi:10.1016/j. drugalcdep.2017.10.002 4. Stein BD, Sorbero M, Dick AW, Pacula RL, Burns RM, Gordon AJ. Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA. 2016;316(11):1211-1212. doi:10.1001/jama.2016.10542 5. Duncan A, Anderman J, Deseran T, Reynolds I, Stein BD. Monthly patient volumes of buprenorphine-waivered clinicians in the US. JAMA Netw Open. 2020;3(8):e2014045. doi:10.1001/jamanetworkopen.2020.14045 6. IQVIA web site. Accessed July 13, 2020. https://www.iqvia.com/solutions/real-world-evidence/real-world-data-and-insights Funding Information: Conflict of Interest Disclosures: Dr Stein reported receiving grants from the National Institutes of Health. Dr Saloner reported receiving grants from the National Institute on Drug Abuse. Dr Schuler reported receiving grants from the National Institute on Drug Abuse and personal fees from the Foundation for Opioid Response Efforts. Mr Sorbero reported receiving grants from the National Institutes of Health. Dr Gordon reported receiving an honorarium from UpToDate and serving on the board of directors for the American Society of Addiction Medicine and the Association for Multidisciplinary Education and Research in Substance Use and Addiction. No other disclosures were reported. Funding Information: Conflict of Interest Disclosures: Dr Werbel reported receiving grants from the American Society of Transplantation Research Network Clinical Science Fellowship Grant. Dr Avery reported receiving grants from Aicuris, Astellas, Chimerix, Merck, Oxford Immunotec, Qiagen, and Takeda/Shire. Dr Segev reported serving as a consultant to and receiving honoraria for speaking from Sanofi, Novartis, CSL Behring, Jazz Pharmaceuticals, Veloxis, Mallincrodt, and Thermo Fisher Scientific. No other disclosures were reported. Funding Information: Funding/Support: This work was supported by the Ben-Dov family; grants F32DK124941 (Dr Boyarsky), K01DK101677 (Dr Massie), and K23DK115908 (Dr Garonzik-Wang) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); grant K24AI144954 (Dr Segev) from the National Institute of Allergy and Infectious Diseases (NIAID); and by grant gSAN-201C0WW from the Transplantation and Immunology Research Network of the American Society of Transplantation (Dr Werbel).",

year = "2021",

month = jun,

day = "1",

doi = "10.1001/jama.2021.4469",

language = "English (US)",

volume = "325",

pages = "2206--2208",

journal = "JAMA - Journal of the American Medical Association",

issn = "0098-7484",

publisher = "American Medical Association",

number = "21",

}

TY - JOUR

T1 - Concentration of patient care among buprenorphine-prescribing clinicians in the us

AU - Stein, Bradley D.

AU - Saloner, Brendan

AU - Schuler, Megan S.

AU - Gurvey, Jill

AU - Sorbero, Mark

AU - Gordon, Adam J.

N1 - Funding Information: Funding/Support: This research was supported by grants R01DA045800, K01DA042139, 1UG1DA049444, and P50DA046351 from the National Institutes of Health. Role of the Funder/Sponsor: The National Institutes of Health had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Additional Contributions: We thank Mary Vaiana, PhD, and Hilary Peterson, BA (both with the RAND Corporation), for their feedback and editorial assistance on earlier versions of the manuscript; Rose Kerber, MPP (RAND Corporation), for assistance with the data; and Mark Totten, MS (RAND Corporation), for input regarding the analysis. None received additional compensation beyond their RAND salaries. 1. Frank JW, Wakeman SE, Gordon AJ. No end to the crisis without an end to the waiver. Subst Abus. 2018;39(3):263-265. doi:10.1080/08897077.2018.1543382 2. Olsen Y, Fitzgerald RM, Wakeman SE. Overcoming barriers to treatment of opioid use disorder. JAMA. 2021;325(12):1149-1150. doi:10.1001/jama.2021.1741 3. Thomas CP, Doyle E, Kreiner PW, et al. Prescribing patterns of buprenorphine waivered physicians. Drug Alcohol Depend. 2017;181:213-218. doi:10.1016/j. drugalcdep.2017.10.002 4. Stein BD, Sorbero M, Dick AW, Pacula RL, Burns RM, Gordon AJ. Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA. 2016;316(11):1211-1212. doi:10.1001/jama.2016.10542 5. Duncan A, Anderman J, Deseran T, Reynolds I, Stein BD. Monthly patient volumes of buprenorphine-waivered clinicians in the US. JAMA Netw Open. 2020;3(8):e2014045. doi:10.1001/jamanetworkopen.2020.14045 6. IQVIA web site. Accessed July 13, 2020. https://www.iqvia.com/solutions/real-world-evidence/real-world-data-and-insights Funding Information: Conflict of Interest Disclosures: Dr Stein reported receiving grants from the National Institutes of Health. Dr Saloner reported receiving grants from the National Institute on Drug Abuse. Dr Schuler reported receiving grants from the National Institute on Drug Abuse and personal fees from the Foundation for Opioid Response Efforts. Mr Sorbero reported receiving grants from the National Institutes of Health. Dr Gordon reported receiving an honorarium from UpToDate and serving on the board of directors for the American Society of Addiction Medicine and the Association for Multidisciplinary Education and Research in Substance Use and Addiction. No other disclosures were reported. Funding Information: Conflict of Interest Disclosures: Dr Werbel reported receiving grants from the American Society of Transplantation Research Network Clinical Science Fellowship Grant. Dr Avery reported receiving grants from Aicuris, Astellas, Chimerix, Merck, Oxford Immunotec, Qiagen, and Takeda/Shire. Dr Segev reported serving as a consultant to and receiving honoraria for speaking from Sanofi, Novartis, CSL Behring, Jazz Pharmaceuticals, Veloxis, Mallincrodt, and Thermo Fisher Scientific. No other disclosures were reported. Funding Information: Funding/Support: This work was supported by the Ben-Dov family; grants F32DK124941 (Dr Boyarsky), K01DK101677 (Dr Massie), and K23DK115908 (Dr Garonzik-Wang) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); grant K24AI144954 (Dr Segev) from the National Institute of Allergy and Infectious Diseases (NIAID); and by grant gSAN-201C0WW from the Transplantation and Immunology Research Network of the American Society of Transplantation (Dr Werbel).

PY - 2021/6/1

Y1 - 2021/6/1

UR - http://www.scopus.com/inward/record.url?scp=85107066958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107066958&partnerID=8YFLogxK

U2 - 10.1001/jama.2021.4469

DO - 10.1001/jama.2021.4469

M3 - Letter

C2 - 34061152

AN - SCOPUS:85107066958

SN - 0098-7484

VL - 325

SP - 2206

EP - 2208

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

IS - 21

ER -

Concentration of patient care among buprenorphine-prescribing clinicians in the us

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this